The Nanomedicine Translation Advisory Board is a service that has been designed as the prime initiative to help the European nanomedicine community not to get lost in translation.

Apply to the TAB

About the nanomedTAB

The mission of the Nanomedicine Translation Advisory Board is to guide and promote innovative nanomedicine projects by providing free strategic advice, support and concrete recommendations. The ultimate mission of TAB is to facilitate access to clinical trials or the market uptake of promising projects supported.

The TAB aims at helping individual actors of the European nanomedicine community to translate their promising projects into innovative products for healthcare by providing a free advisory service based on the high-level experience of seasoned nanomedicine translation experts.

The process:

  • Stage-gate service that offers free one-to-one advice sessions to the European nanomedicine community at any stage of their nanobiomedical endeavours. Duration and depth of the advisory service depends on the merit of each project to qualify for the different stages of the service.
  • The content is driven by the needs each project brings, and tailored to the beneficiaries’ ultimate concerns and expectations. It may include topics such as R&D; process development, optimisation and scale-up; safety and quality control; clinical investigation; regulatory and reimbursement issues; intellectual property rights and licensing; business strategy, business modelling and development, funding strategies; networking, collaboration, commercialisation.
  • Advice aims at responding to projects’ needs including access to clinical centres for first studies in patients, financial resources from investors and/or large companies to accelerate critical steps to market.
  • Most promising projects will be eligible for further high value services such as showcase opportunities to clinical trial centres, investors and large companies. Special coaching sessions may be organised prior to showcasing events.
  • The nature of the advice and recommendations to be provided is not binding, meaning that beneficiaries may or not follow advice and recommendations at their own discretion.

 

Project Image

What the community is saying about us

News and upcoming Events

7th Jul

Third cut-off date of the TAB

The cut-off date for the 3rd TAB-in Sessions, in Heraklion, Crete, has been anounced. Submit your projects untill the 31st of July and be the next project to join the 29 projects already being supported by the TAB in the road to Nanomedicine Translation.

28th Jun

TAB-In sessions in Basel

Projects selected in the 2nd cut-off will be invited to join 2-hours individual sessions with experts in Basel. The TAB-In Sessions are the entry point to the support service offered by the TAB.

8th May

Second cut-off date of the TAB

The TAB is already supporting 20 projects from different countries in Europe. Don’t miss out the opportunity to apply and benefit from TAB support as well!

2016 JUNE PR

The NanomedTAB
ROUND 3 BEGINS

2016 Flyer

Feel free to share the flyer with your social and business networks

Code of Conduct

Please make sure you read the Code of Conduct before applying to the TAB

Our Experts

David Bott Linkedin

David Bott

David has over 25 years experience in developing and commercializing materials technologies with British Petroleum, Courtaulds, and ICI in a variety of roles. He retired from corporate life in 2004 to develop his growing interest in small, high technology companies.

This led to him becoming the Chairman of Oxford Biomaterials and a non-executive Director of Oxford Advanced Surfaces. He also spent some time as an advisor to FirstVentures, a Venture Capital Fund focusing on advanced materials and nanotechnology.

In 2006 he was also appointed part time CEO of Materials UK, a organisation set up to implement and develop the work of the Materials Innovation and Growth team. Meanwhile, in 2004, a chance meeting with an uncharacteristically interesting civil servant led to some involvement with the Innovation Group of the DTI. This, in turn, led to his appointment in July 2007 as the Director of Innovation Platforms for the new Technology Strategy Board.

This evolved into responsibility for all Innovation Programmes the following year and, before he left at the ned of 2013, he was additionally responsible for Communications. He is now a Principal Fellow at WMG, at the University of Warwick.

Eckhard Schwenner Linkedin

Eckhard Schwenner

Having lived and worked in Germany, the USA, Japan and the Netherlands with recent working experience in the growth markets of China and India, Eckhard Schwenner has a wide international management experience accumulated over 30 years in international leadership positions within the Healthcare industry.

Strong track record in Business, Program Management, R&D and Strategy roles in Pharmaceuticals and Diagnostics Business Groups in Bayer AG (VP Diagnostics); Siemens (CEO pes) and Philips (CEO Healthcare Incubator Emerging Markets). Eckhard Schwenner also has recognized achievements in the development and implementation of strategic concepts on a global basis for multi-divisional corporations and in leading complex multidisciplinary programs to successful commercialization.

Eckhard Schwenner’s experience also includes Start Up and deal making successes as CEO of pes diagnosesysteme, an immunoassay bases Point of Care company and enverdis, a German Cardiovascular Devices and Diagnostics Medtech company.

Since 2013 Eckhard Schwenner works as a consultant for start up businesses in the Healthcare/Lifesciences Industry, also providing interim management.

Eric Mayes Linkedin

Eric Mayes

Eric Mayes is CEO of Endomag and has over 15 years’ experience in developing and leading materials technology companies spanning data storage, display technology, printed electronics and medical devices. Eric has led the oncology-focused Endomag through rapid growth since marketing its first nanoparticle device for staging breast cancer in late 2012.

Prior to joining Endomag in 2010, Eric served as Director of Commercial Development for Cambridge Display Technology (CDT) that was sold to Sumitomo Chemical in 2007 for $285m. Prior to CDT, he served as CEO of NanoMagnetics that developed high performance materials for the data storage industry. He was named the Royal Society of Chemistry’s “Entrepreneur of the Year 2003” for his founding role in NanoMagnetics.

With a strong interest in supporting the translation of scientific research, Eric lectures internationally on nanomaterials commercialisation and technology entrepreneurship. He is an advisor to the University of Texas at Austin’s “Texas Health Catalyst” and the European Nanomedicine Translation Advisory Board (TAB). A US-UK dual national, he holds a BSc in Physics from Arkansas State University and a PhD in Chemistry from the University of Bath. Eric is a Fellow of the Royal Society of Chemistry.

Florian Kemmerich Linkedin

Florian Kemmerich

Florian is Principal & Founder of Ryan-Kay, Partner/Advisor of several investment funds and Board Member of numerous organizations. He holds a Bachelor of Business Administration, Master of Science in Marketing and different diploma on business and personal development. As a corporate advisor and CEO mentor he leverages his extensive background on start-ups in biotech, medical device and life science to help building and repositioning organizations in the competitive global marketplace.

Passionate about regenerative medicine, growth factors, stem cells and biologics, Florian has a proven track record of building and leading innovative and effective commercial stage companies. Amongst others he has held C-Level positions at B. Braun Medical, Olympus Biotech and Small Bone Innovations (now Stryker). Fluent in German, English, Spanish, French and Italian.

Laurent Levy Linkedin

Laurent Levy

Laurent holds a doctorate in physical chemistry, specialized in nanomaterials, from the Pierre and Marie Curie University (Paris) and from the CEA (Commissariat à l'Énergie Atomique et aux Énergies Alternatives) and a DEA (advanced studies and diplomas) in physics of condensed matter from the UPVI-ESPCI (Paris). He has extensive experience in sciences and techniques related to nanotechnology, a field in which he has worked for more than 10 years. His research at the frontier of biotechnology and nanotechnologies has resulted in the development of a number of concrete applications such as NanoXray, which could open a new method for cancer treatment.

For many years, Laurent was a consultant in the development of application of nanotechnologies with large companies such as Sanofi (pharma), Guerbet (medical imaging), Rhodia (chemistry), as well as for biotechnology start-ups. Laurent is the author of 35 international scientific publications and communications. He has applied for several patents and completed his training with a post-doctoral fellowship at the Institute for Lasers, Photonics and Biophotonics, SUNY (State University of New York), Buffalo, USA. He is since October 2012 the vice-chair of the ETP Nanomedicine (ETPN) and is involved with many international groups working in the field.

Mike Eaton Linkedin

Mike Eaton

Mike Eaton worked in research in the Pharma industry for more than 35 years. Initially at GD Searle, where he built the first synthetic gene for Urogastrone and sequenced human fibroblast interferon. He was a founding member of Celltech in 1980; later acquired by UCB. He has worked on a number of marketed drugs - Mylotarg in 2000, the first Antibody drug conjugate and Certolizumab Pegol in 2009, the first PEGylated antibody. Unusually he has worked with both small molecules and large molecules, including DNA.

He built the first automated DNA synthesiser in Europe, which is now owned by the Science Museum in London. This machine was used for the first cloning of pre-prochymosin, a key ingredient in cheesemaking.

He has worked on low molecular weight drugs including the first non-emetic PDEIV inhibitor. Mike is a special professor at Nottingham University and was an executive board member of the European Technology Platform for Nanomedicine, at its inception in 2005. He left UCB in February 2010 and is now a strategic and technical adviser to a number of companies. His particular interest is commercial translation of nanotechnology research to nanomedicines – medicines to help patients.

His article Delivering Nanomedicines to Patients: A Practical Guide, Mike A.W. Eaton, Laurent Levy, Olivier M.A. Fontaine, Nanomedicine: Nanotechnology, Biology and Medicine, May 2015 Volume 11, Issue 4, Pages 983–992 is an important reference for developers.

Rüdiger Iden Linkedin

Rüdiger Iden

Rüdiger Iden has thirty years of experience in the businesses of coatings, pigments and high performance plastics segments, and more than ten years in actively creating markets for chemical nanotechnology. 1977, degree in Chemistry, Julius-Maximilian University, Wuerzburg; 1981, PhD in Chemistry, Wuerzburg University. With BASF: 1981, Research Scientist, Colorants Laboratory; Head, Computational Chemistry, Main Laboratory; 1987, Assistant to Chairman of the Board of Executive Directors; 1991, Head, Colorants Research; 1996, Head, Pigment Research; since 1999, Head, Physics Research; between 2002 and 2010, Senior Vice-President; since 2002, Spokesman for Nanotechnology. 2004, Honorary Professor, University of Duesseldorf. Chairman, Chemical Nanotechnology Working Group, DECHEMA, Frankfurt. Co-Chair, European Technology Platform for Sustainable Chemistry, Brussels. Member, NanoBusiness Alliance Advisory Board. Chairman of the Board, Southern German Plastics Centre, Würzburg, Member of the German Academy of Science – acatech, Co-Chair German Platform NanoBioMedicine (since 2015).

Stephan Lensky Linkedin

Stephan Lensky

Stephan Lensky is a consultant to the international biotech industry. He brings more than 20 years of experience in Pharma companies, more than 15 years of experience in business development, and more than 5 years of international leadership to start-ups. Currently he is acting as a Chief Operating and Chief Business Officer of EpimAb Biotherapeutics, Inc., a start-up based in Shanghai, China. Prior to being a consultant, Stephan was a Corporate Vice President at Boehringer Ingelheim, located in Germany, with additional groups reporting to him in Ridgefield, Connecticut, and Tokyo. His Department was globally responsible for the negotiation and management of all strategic transactions. He also worked in various areas of research as well as in marketing & sales during his years at Boehringer Ingelheim and Bayer Health Care. Stephan holds a Ph.D. in Chemistry.